Moreover, RESILIENT project will offer a protocol for the study in vivo and ex vivo of leptin sensitivity that can be reproduced for evaluating metabolic and cognitive effects of anti-obesity medications, i.e. not just glucagon like peptide 1 and setmelanotide, but also amylin. This evidence concerns the gene IAPP and obesity disorder.